Published in final edited form as:

Semin Nephrol. 2009 July ; 29(4): 425–434. doi:10.1016/j.semnephrol.2009.03.017.

Current Advances in Chronic Kidney Disease in Children: Growth, Cardiovascular, and Neurocognitive Risk Factors

Larry A. Greenbaum, MD, PhD [Division Director],

Pediatric Nephrology, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA

Bradley A. Warady, MD [Professor of Pediatrics], and

University of Missouri-Kansas City School of Medicine, Associate Chairman, Department of Pediatrics, Chief, Pediatric Nephrology, The Children's Mercy Hospital, Kansas City, MO, USA

Susan L. Furth, MD, PhD [Associate Professor of Pediatrics]

Departments of Pediatrics and Epidemiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Abstract

Linear growth and neurocognitive development are two of the most important differences between adults and children, in terms of clinical issues that must be addressed in patients with chronic kidney disease (CKD). Correction of metabolic acidosis, nutritional deficiency, and renal osteodystrophy improve linear growth, but many children require administration of growth hormone to achieve normal growth. A variety of neurocognitive deficits occur in children with CKD, although there has been an improvement in outcome via improved dialysis, correction of malnutrition, and decreased aluminum exposure. While growth and neurocognitive development are delayed, cardiovascular complications are accelerated in children with CKD, and are reflected in a dramatic increase in cardiovascular mortality compared to healthy children. Other early cardiovascular complications in children with CKD include left ventricular hypertrophy, cardiac dysfunction, and vascular calcifications.

Keywords

Chronic kidney failure; human growth hormone; developmental disabilities; cardiovascular diseases

Growth in CKD

CKD has a negative effect on linear growth; short stature occurs in the majority of adults who develop CKD during childhood.¹ Growth retardation is especially severe during the first year of life, and thus younger age of onset of CKD is associated with a more severe height deficit. ² Children who have congenital CKD typically fall below the 3rd percentile during the first 15 months of life and then grow at a rate that allows them to parallel the growth curve, albeit

© 2009 Elsevier Inc. All rights reserved.

Correspondence to: Larry A. Greenbaum, MD, PhD, Division of Pediatric Nephrology, Emory University, 2015 Uppergate Drive, NE, Atlanta, GA 30322, Phone: (404) 727-6994, Fax: (404) 727-8213, Lgreen6@emory.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

below the 3rd percentile.³ Growth retardation tends to be proportional to the decrement of GFR,³ although even children with stage 3 CKD (est GFR 30–59 ml/min/1.73m²) can have a height below the 3rd percentile.² The pubertal growth spurt is delayed, shortened, and associated with a reduced growth velocity, contributing to the loss in adult height.⁴ Children receiving dialysis have more profound growth retardation than those receiving conservative management or with a renal transplant.⁵ While growth velocity improves following transplantation, most children do not have catch-up growth, so their height standard deviation score (SDS) does not improve.¹ Both decreased GFR and steroid use¹ may impair growth after transplantation.

Along with affecting adult height, poor growth in children with CKD is associated with increased morbidity and mortality.^{6–8} In a study of children receiving dialysis, each one SDS decrease in height was associated with a 14% increase in the risk of mortality.⁶ Similarly, in patients receiving dialysis or with kidney transplants, the children with moderate or severe growth failure had an increased risk of hospitalization and death.⁷ Finally, a height below the first percentile at dialysis initiation was associated with an increased risk of hospitalization and death.⁸

A variety of factors cause growth retardation in children with CKD (Table 1); some are amenable to treatment. Isolated metabolic acidosis, as occurs in children with renal tubular acidosis, causes growth retardation and can be treated with base therapy. Sodium wasting also occurs as a result of renal tubular disorders in children, may contribute to poor growth and can be treated with enteral sodium supplementation.⁹ Similarly, renal osteodystrophy, a potential cause of poor growth and bone deformities in children with CKD,¹⁰ can be treated with dietary phosphate restriction, phosphate binders, and activated vitamin D sterols.¹¹ Use of activated vitamin D sterols improves growth in children with CKD,¹² but excessive suppression of PTH may diminish growth.¹³ Inadequate caloric intake in children with CKD, which may lead to malnutrition,¹⁴ is treated with nutritional intervention; tube feeding is often necessary in infants. The positive effect of aggressive caloric intervention on growth has been demonstrated in infants, but not in older children.⁹

Growth Hormone Therapy in CKD

Growth hormone (GH), which is secreted by the pituitary gland, is necessary for linear growth during childhood; it mediates most of its actions by stimulating the synthesis of insulin like growth factor I (IGF-I).¹⁵ Children with CKD have normal or elevated levels of GH, but GH is less effective at stimulating linear growth in the setting of impaired kidney function. There are multiple mechanisms that explain the decreased efficacy of GH in children with CKD, including decreased hepatic synthesis of IGF-I,¹⁵ decreased bioavailability of IGF-I due to higher levels of IGF-I binding proteins,¹⁶ and end organ resistance to GH.¹⁷

The resistance to GH in children with CKD can be overcome via administration of recombinant human GH (rhGH). Randomized studies of rhGH in children with predialysis CKD were performed following initial promising results in nonrandomized studies.^{18, 19} In a two year, placebo-controlled study involving 125 prepubertal children, the group that received rhGH had significantly better growth than the placebo group during both years of the study, but the difference was greater during the first year of treatment.¹⁸ Children receiving dialysis respond to rhGH, but the effect is less dramatic than in the predialysis population.^{20, 21}

There are also a number of studies demonstrating the efficacy of rhGH in children who have short stature following kidney transplantation.^{22, 23} Along with short-term benefits, rhGH in children with CKD results in improved adult height.²¹

Prior to use of rhGH, children should have correction of metabolic acidosis, renal osteodystrophy and nutritional deficiencies. Treatment with rhGH should be initiated in

children who are below the 3rd percentile for height or who have linear growth below the 3rd percentile. Secondary hyperparathyroidism may worsen with rhGH;²⁰ parathyroid hormone levels should be monitored before and after initiating therapy.²⁴

Intracranial hypertension, which may present with headache, papilledema, visual changes, nausea, or emesis, is a rare complication of rhGH therapy in children with CKD.²⁵ There is a question about whether rhGH might increase the risk of acute rejection in transplant recipients, but most studies have not supported this concern.^{22, 23} Despite isolated case reports, there is no evidence that rhGH increases the risk of malignancy or pancreatitis,²⁵

Despite the efficacy of rhGH in correcting short stature in children with CKD, the majority of children who are eligible do not receive this therapy.²⁶ The requirement for daily injections is an obvious barrier to therapy, and it is clear that psychosocial factors are an important cause of low rhGH utilization.²⁷ Nevertheless, it appears that rhGH is not offered to some children without obvious contraindications; short girls are significantly less likely to receive rhGH than short boys.²⁷ Insurance approval may be an important cause of delays in patients receiving rhGH.²⁷

Cardiovascular Disease

Cardiovascular mortality in children and young adults with end stage renal disease (ESRD) is several orders of magnitude greater than nationally reported health statistics for similar age groups. According to the U.S. Renal Data System (USRDS) Annual Report, cardiovascular mortality among pediatric patients with ESRD has been rising, from 17.7 deaths per 1,000 patient years at risk in 1991 to 23.4 in 2005.²⁸ Deaths attributed to cardiovascular disease (CVD) are highest among African American children and young adults on dialysis. In the registry of the North American Renal Trials and Collaborative Studies (NAPRTCS), 22.8% of 471 deaths in pediatric dialysis patients were attributed to cardiopulmonary causes.²⁹ Although there is some concern that deaths attributed to cardiovascular disease in claims data or registries may be misclassified, closer inspection of cardiovascular disease endpoints in the USRDS database by Chavers et al³⁰ confirmed the high prevalence of CVD in this population, revealing that 31.1% of incident pediatric dialysis patients aged 0 – 19 years experienced a cardiac related event in up to 7 years of follow-up. Arrhythmias occurred at approximately 91 – 128.6 events per 1000 patient years at risk, while cardiomyopathy was reported at rates of 42 – 85 events per 1000 patient years at risk. Valvular disease and cardiac arrest were also reported, but were less common than arrhythmias and cardiomyopathy.³⁰ Sudden death in the pediatric CKD and ESRD population may be the result of fatal arrhythmias, possibly related to dilated, hypertrophic cardiomyopathies or acute changes in electrolyte balance.

Cardiovascular Disease Risk Factors in Children

In adults, “traditional” and “CKD-related” risk factors have been associated with cardiovascular disease. In adults, traditional risk factors for CVD events include increasing age, white race, male gender, hypertension, left ventricular hypertrophy (LVH), dyslipidemia, diabetes mellitus, tobacco use, physical inactivity, psychosocial stress, positive family history of CVD, and obesity.³¹ In children, adolescents are at higher risk of CV events than younger children, and African American race and female gender have been reported to be risk factors for CVD in children and adolescents on dialysis.³⁰

Hypertension

Hypertension (HTN), as measured by casual blood pressure or ambulatory blood pressure monitoring (ABPM), accelerates CKD progression and is exacerbated by the decline in kidney function.^{32, 33} In a North American registry of children with chronic renal insufficiency,

children who were hypertensive at the time of enrollment developed ESRD or loss of GFR > 10 ml/min/1.73m² significantly more often than normotensive children with CKD.³⁴ In a cross-sectional study of North American children with mild to moderate CKD, hypertension was quite common.³⁵ For systolic BP, 17% had uncontrolled HTN (BP > 95th percentile) and 7% pre-HTN (BP 90-95th percentile). The overall prevalence of systolic HTN (controlled and uncontrolled) was 53%. For diastolic BP, 16% had uncontrolled HTN, and 11% pre-HTN. The overall prevalence of diastolic HTN (controlled and uncontrolled) was 54%. After adjusting for multiple variables, male sex (PR 1.7, 95% CI 1.0,2.6, p=0.03); nephrotic-range proteinuria (PR 1.6 95% CI 1.1,2.6, p=0.02) and not using ACE/ARB (PR=1.5, 95% CI 1.0,2.3, p=0.06) were associated with the presence of uncontrolled HTN. The finding that a significant proportion of children with CKD have elevated BP, while about one-third of these children were not receiving antihypertensive medication, indicates that HTN, an important risk factor for CVD in pediatric CKD, is frequently under-treated. More aggressively treating hypertension is a clear opportunity to improve and perhaps ameliorate the burden of CVD in children, adolescents, and young adults with CKD. Of note, proteinuria, a putative risk factor for CKD-related CVD in adults, was a significant risk factor for hypertension in this baseline pediatric study.³⁵

ABPM has recently been shown to facilitate a more accurate diagnosis of HTN in children and also to predict hypertensive target-organ damage.^{36, 37} In small studies in children, abnormalities of ABPM have been associated with target organ damage, including increased carotid intima medial thickness (cIMT), and left ventricular hypertrophy (LVH).^{38, 39}

Left Ventricular Hypertrophy

LVH has been reported as a risk factor for CVD in adults. Mitsnefes et al, assessed left ventricular mass (LVM) in 25 children with mild-to-moderate CKD, and found that 22% of CKD patients had LVH or developed LVH in 2 year follow-up.⁴⁰ Eccentric LVH was the most common geometric pattern. Regression analysis showed that a lower initial LVM index and hemoglobin level and an interval increase in intact parathyroid hormone level and nighttime SBP load independently predicted the interval increase in LVM index.

Mitsnefes et al assessed LV function in children with CKD versus controls^{41, 42} and found that children with CKD, on chronic dialysis and following transplant had impaired diastolic function. An increased LVM index was the only measured independent predictor for diastolic dysfunction in these patients.

Dyslipidemia

CKD and ESRD are associated with increased circulating concentrations of triglycerides (TG) and triglyceride-rich lipoproteins, and decreased concentrations of high-density lipoproteins (HDL).^{43, 44} This pattern of dyslipidemia is atherogenic and therefore is likely to contribute to elevated CVD risk. Dyslipidemia is increasingly believed to facilitate the genesis and progression of CKD.⁴⁵

Anemia

In adults with CKD, observational evidence demonstrates an association between anemia and LVH.⁴⁶ Higher hemoglobin levels have been associated with improved oxygen utilization, exercise capacity, and cardiac function. Evidence supporting cardiac benefits associated with the treatment of anemia in children with CKD is limited, although some reports describe an improvement in cardiac geometry.^{47, 48} A single, blinded crossover trial of 11 children aged 2 – 12 years on dialysis demonstrated an improvement in cardiac index by 6 months and a significant reduction in LVM by 12 months in anemic children treated with an erythropoietin

stimulating agent.⁴⁹ Two additional observational studies of patients with severe LVH demonstrated that children with lower Hb levels had more severe LVH, and lower left ventricular compliance.⁴¹

Abnormal calcium and phosphorus

CKD is associated with a marked prevalence of arterial calcification in both adults and children.⁵⁰ Elevated serum levels of calcium and phosphate have been recognized as risk factors for vascular calcification in both observational and interventional studies in CKD. In a number of studies, detection of arterial calcium with electron beam computer tomography or carotid ultrasound has been associated with CVD. In a study of 44 pediatric patients with CKD stages 2 – 4 and 16 patients on dialysis, Mitsnefes et al found that an increased calcium-phosphorus product predicted increased cIMT. Increased serum phosphorus and PTH predicted increased arterial stiffness.⁵¹ Thus vascular abnormalities appear to already be present in children and adolescents during early stages of CKD, and these appear to be related to abnormal calcium-phosphorus metabolism.

Chronic inflammation

Chronic inflammation is a feature of patients with ESRD, and increased levels of inflammatory markers have been detected in both adults and children at earlier stages of CKD.^{52, 53} Circulating inflammatory cytokines have been suggested as mediators in the progression of CKD and as an important link between CKD and CVD risk factors. Pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α), have been linked to increased atherogenesis as well as increased morbidity and mortality among adults with ESRD.⁵⁴ Elevated circulating levels of IL-6 have been linked to hypertension, LVH, atherosclerosis and cardiac mortality among adults with ESRD.⁵⁵ The balance between the pro-inflammatory cytokine interleukin-1 (IL-1) and the anti-inflammatory cytokine IL-1RA has also been shown to predict CV outcome in adult patients. Interleukin-10 is an anti-inflammatory cytokine that is known to attenuate the inflammatory response, and low levels have been found to be associated with increased CV mortality among adults.⁵⁶

A significant number of young adults with childhood onset of CKD have demonstrated systemic vascular atherosclerosis, endothelial dysfunction, and coronary artery disease.^{57, 58} Local overexpression of the renin-angiotensin-aldosterone system, adrenergic system, and inflammatory cytokines may contribute to cardiac and vascular changes in CKD.

Novel CVD Risk Factors

In addition to traditional CVD risk factors in CKD, a number of novel risk factors for CVD have recently gained attention. An abnormal birth history is extremely common in children with CKD, particularly those with underlying urologic disease. A growing body of evidence supports the Barker hypothesis, which contends that low birth weight (LBW; < 2500 g) places patients at increased risk for development of a variety of problems including obesity, type II diabetes and CVD.⁵⁹ Likewise, the Brenner hypothesis argues that LBW is associated with a reduction in nephron number, which increases the risk for hypertension and CKD.⁶⁰

LBW or prematurity has been associated with CVD risk factors in children without kidney disease. A study by Bayrakci et al, in which ABPM was performed in 41 children born preterm,⁶¹ showed the preterm group had higher nocturnal systolic BP, elevated nocturnal systolic and diastolic BP loads, and blunted nocturnal dipping. In normal children, in two studies by Furth and colleagues, infants who were SGA were not at increased risk for high blood pressure at 7 years of age. However, children who crossed weight percentiles upward during early childhood had an increased risk. In a separate analysis of the 29,710 mother-child pairs from the

Collaborative Perinatal Project, there was a significant interaction between race and BW in predicting SBP ($p=.002$). LBW did not predict elevated SBP in blacks.⁶²

Recent studies have suggested that low vitamin D levels are highly prevalent in individuals with CKD, and may be an important risk factor for CVD.⁶³ Vitamin D deficiency is widely recognized in adults with CKD, and recently confirmed in children with ESRD.⁶⁴ In one study, 92% of children had 25-hydroxy vitamin D deficiency and 36% had 1,25-dihydroxy vitamin D deficiency (1,25(OH)₂D) deficiency. Vitamin D is believed to play a role in the development of CVD by decreasing renin levels, controlling inflammation, and down regulating vascular endothelial cell proliferation.^{65, 66} In children on dialysis, low Vitamin 1,25(OH)₂D₃ levels have been associated with increased cIMT.⁶⁴

Neurocognitive Effects of CKD

The cognitive development of infants and children with CKD is an area of study that has, until recently, received little attention with little discrimination between those with ESRD and those with earlier stages of CKD.⁶⁷ This is all the more interesting given the long-term and significant clinical manifestations that abnormalities of cognition may have on patient outcome. Early reports, such as those of Rotundo, et al and McGraw and Haka-Ikse, revealed findings of profound developmental delay in 60–85% of infants with severe renal insufficiency, with delays in gross motor and language development being most common.^{68–70} In the former study, 20 of 23 infants exhibited an encephalopathy characterized by developmental delay, microcephaly, hypotonia, seizures, and dyskinesia.⁶⁸ All of this occurred in the setting of a uremic milieu and during a critical period of brain development that persists through the initial 6–12 months of life and that is typically associated with 50% of post-natal brain growth.⁷¹ Subsequent recognition of the crucial role that aluminum exposure and malnutrition played in this scenario and the resultant introduction of improved dialysis water purification techniques, the avoidance of aluminum containing phosphate binders and the aggressive use of supplemental feeding methods has led to improved neurodevelopmental outcomes overall, despite the finding of non-specific EEG abnormalities, the possibility of delayed myelination of the somatosensory cortex and/or the increased risk for central nervous system structural abnormalities (eg atrophy and infarcts) in some patients.^{72–74}

In one of several studies that addressed the general development of young patients, Hulstijn-Dirkmaat et al compared the development of 15 toddlers with CKD who were being conservatively managed with that of 16 children who were receiving dialysis therapy.⁷⁵ The patients with CKD performed better than those on dialysis as reflected by their achievement of a higher developmental index. Honda et al examined the growth and development of 15 children < 2 years of age and receiving peritoneal dialysis (PD) and found that the developmental quotient (DQ) was normal (> 80%) in only 2 patients, although 3 of 4 patients with the lowest DQ suffered cerebral infarctions or Jeune syndrome to account for some of the findings.⁷⁶ In one of the larger reports, Warady et al described the neurocognitive status of 28 infants at 1 year of age, all of whom had initiated long-term peritoneal dialysis and supplemental tube feedings during the first 3 months of life, with no exposure to aluminum.⁷⁷ The general development of 22 (79%) of the infants fell in the normal range and only 1 (4%) patient was categorized as impaired, although 12 patients were mildly hypotonic. Finally, Ledermann et al described the outcome of 8 children who initiated PD during infancy, and 2 (25%) of these patients demonstrated developmental delay when evaluated at < 5 years of age.⁷⁸ Thus, it appears that at least 25% of infants and toddlers who have severe renal insufficiency will exhibit developmental delay, whereas the impact of milder forms of CKD on the neurodevelopment of infants is unknown.

The availability of intelligence quotient (IQ) data as a measure of cognitive function in older children with CKD has provided additional valuable information.^{72, 76–80} Honda et al found that at 5–6 years of age, the mean IQ of 9 of their patients was 80.6 and 6 of the patients scored more than 85 ($> -1SD$) and attended a normal school.⁷⁶ Warady et al found that of 19 children retested at > 4 years of age (mean age: 6.6 ± 1.3 years), 15 (79%) had a normal IQ, although only 72% and 56% of these patients scored in the average range on tests of verbal and nonverbal functioning, respectively.⁷⁷ Almost all of these patients had been transplanted and of the 16 school-aged patients, 15 (94%) were attending school as full-time students in an age-appropriate classroom. Of 8 patients ≥ 5 years of age in the cohort followed by Ledermann et al, 2 (25%) exhibited general developmental delay and were receiving teaching support in a normal school setting.⁷⁸ Brouhard et al described a significantly lower IQ in children with CKD when compared to their sibling controls.⁸¹ Most recently, Madden et al reported on the cognitive and psychosocial outcome of 16 infants who began PD during the first year of life, the majority (75%) of whom had a functioning transplant at the time of their reassessment at a mean age of 5.8 years.⁷⁹ Ten (67%) children had an IQ that fell in the normal range, while 13 of 15 (87%) had an IQ score within 2SDs of the norm. Finally, in studies that compared the results of transplanted patients to those remaining on dialysis, Lawry et al found that the mean IQ of the transplanted population was higher than that of the dialysis group (although the results of both groups were in the average range), while Brouhard et al conducted a cross-sectional study and did not find any difference in the mean IQ of the two patient groups.^{81, 82} Improvement in some neurocognitive functions have, however, been seen following transplantation (see below).⁸⁰ Thus, this information suggests that children with CKD tend to score lower than normal children on tests of general cognitive functioning, although the results in many patients can be quite good. Whereas recent work has provided preliminary support of the concept that an increased severity of CKD correlates with a lower IQ and may help explain some of the differences in outcome noted above, additional studies in this area are needed, with particular reference to patients who have only mild-moderate CKD.^{81–84}

Specific Neurocognitive Functions

In addition to studies focused on the general cognitive development of children with CKD, a number of publications have reported on the evaluation of specific neurocognitive functions. Fennell et al conducted many of the early investigations and found that children with CKD had deficits in verbal abstraction abilities and that verbal performance progressively worsened with a greater duration of kidney failure.^{85, 86} These authors also documented that children with CKD exhibited deficits in visual-motor abilities.⁸⁵ In the area of attention and executive function (control processes that are linked to the integrity of the prefrontal cortical regions in the brain and that involve abilities such as problem solving), Fennell et al reported that patients with CKD exhibited poorer sustained attention skills compared to matched controls.^{85, 86} Mendley and Zelko reported improvements in sustained attention and mental processing speed 1 year after transplantation.⁸⁰ Similarly, Qvist et al found no group deficits in attention when comparing transplant recipients to a normal population, although 24% of patients exhibited reduced attention spans.⁷² Gipson and her colleagues have now assumed a leadership role in this area of study and recently evaluated 20 children and adolescents and controls and found that the CKD group was deficient in their initiation and sustaining behaviors within the executive function domain, even when controlling for IQ and chronologic age.⁸⁷

Evaluation of memory is of importance because of its critical contribution to success in school and employment. In addition to the report by Fennell et al of lower memory scores for tasks requiring immediate recall in CKD patients versus controls, Gipson et al found that children with CKD had significantly lower memory abilities than controls with an emphasis on short-term verbal memory, short-term visual memory and new learning.^{86, 87}

In summary, children with CKD are at risk for impairments of overall cognitive functioning, the development of which may be related to the severity and duration of renal insufficiency, patient age and associated medical disorders such as hypertension.⁸⁸ When cognition is impaired, academic functioning may prove suboptimal with particular reference to skills in reading, writing and mathematics, findings that emphasize the necessity of early screening for deficits with a standardized battery of neurocognitive assessments and aggressive intervention when deficits are detected.^{83, 89, 90} Persistence of the neurocognitive impairment into adulthood is possible and can be especially problematic.⁹¹ Ideally, multicenter initiatives like the Chronic Kidney Disease in Childhood (CKiD) study,⁹² will soon provide additional valuable insights into the development and evolution of neurocognition across the spectrum of renal insufficiency in this vulnerable population.

References

1. Hokken-Koelega AC, van Zaal MA, van Bergen W, de Ridder MA, Stijnen T, Wolff ED, et al. Final height and its predictive factors after renal transplantation in childhood. *Pediatr Res* 1994;36:323–328. [PubMed: 7808828]
2. Ho, M.; Stablein, DM. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Annual Report. Maryland: Rockville; 2003.
3. Schaefer F, Wingen AM, Hennicke M, Rigden S, Mehls O. Growth charts for prepubertal children with chronic renal failure due to congenital renal disorders. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. *Pediatr Nephrol* 1996;10:288–293. [PubMed: 8792392]
4. Schaefer F, Seidel C, Binding A, Gasser T, Largo RH, Prader A, et al. Pubertal growth in chronic renal failure. *Pediatr Res* 1990;28:5–10. [PubMed: 2377395]
5. Mehls O, Ritz E, Hunziker EB, Tonshoff B, Heinrich U. Role of growth hormone in growth failure of uraemia—perspectives for application of recombinant growth hormone. *Acta Paediatrica Scandinavica - Supplement* 1988;343:118–126. [PubMed: 3195329]
6. Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, et al. Anthropometric measures and risk of death in children with end-stage renal disease. *Am J Kidney Dis* 2000;36:811–819. [PubMed: 11007685]
7. Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR. Growth failure, risk of hospitalization and death for children with end-stage renal disease. *Pediatr Nephrol* 2002;17:450–455. [PubMed: 12107811]
8. Furth SL, Stablein D, Fine RN, Powe NR, Fivush BA. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. *Pediatrics* 2002;109:909–913. [PubMed: 11986455]
9. Sedman A, Friedman A, Boineau F, Strife CF, Fine R. Nutritional management of the child with mild to moderate chronic renal failure. *J Pediatr* 1996;129:13–18.
10. Salusky IB. Bone and mineral metabolism in childhood end-stage renal disease. *Pediatr Clin North Am* 1995;42:1531–1550. [PubMed: 8614599]
11. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. *Kidney Int* 2001;59:1187–1201. [PubMed: 11231381]
12. Chesney RW, Moorthy AV, Eisman JA, Jax DK, Mazess RB, DeLuca HF. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. *N Engl J Med* 1978;298:238–242. [PubMed: 201843]
13. Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. *Kidney Int* 1998;53:205–211. [PubMed: 9453020]
14. Chantler C, Holliday MA. Growth in children with renal disease with particular reference to the effects of calorie malnutrition: a review. *Clin Nephrol* 1973;1:230–242. [PubMed: 4206019]
15. Roelfsema V, Clark RG. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. *J Am Soc Nephrol* 2001;12:1297–1306. [PubMed: 11373355]

16. Powell DR, Liu F, Baker BK, Hinzt RL, Kale A, Suwanichkul A, et al. Effect of chronic renal failure and growth hormone therapy on the insulin-like growth factors and their binding proteins. *Pediatr Nephrol* 2000;14:579–583. [PubMed: 10912522]
17. Schaefer F, Chen Y, Tsao T, Nouri P, Rabkin R. Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. *J Clin Invest* 2001;108:467–475. [PubMed: 11489940]
18. Fine RN, Kohaut EC, Brown D, Perlman AJ. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. *J Pediatr* 1994;124:374–382. [PubMed: 8120705]
19. Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Wit JM, Wolff ED, de Jong MC, et al. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. *Lancet* 1991;338:585–590. [PubMed: 1715501]
20. Berard E, Crosnier H, Six-Beneton A, Chevallier T, Cochat P, Broyer M. Recombinant human growth hormone treatment of children on hemodialysis. French Society of Pediatric Nephrology. *Pediatr Nephrol* 1998;12:304–310. [PubMed: 9655363]
21. Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. *N Engl J Med* 2000;343:923–930. [PubMed: 11006368]
22. Broyer M. Results and side-effects of treating children with growth hormone after kidney transplantation—a preliminary report. Pharmacia & Upjohn Study Group. *Acta Paediatrica Supplement* 1996;417:76–79. [PubMed: 9055918]
23. Tonshoff B, Haffner D, Mehls O, Dietz M, Ruder H, Blum WF, et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Members of the German Study Group for Growth Hormone Treatment in Children with Renal Allografts. *Kidney Int* 1993;44:199–207. [PubMed: 7689125]
24. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children with Chronic Kidney Disease. *Am J Kidney Dis* 2005;46:S1–S122.
25. Fine RN, Ho M, Tejani A, Blethen S. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. *J Pediatr* 2003;142:539–545. [PubMed: 12756387]
26. Seikaly MG, Salhab N, Warady BA, Stablein D. Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS. *Pediatr Nephrol* 2007;22:1195–1204. [PubMed: 17530299]
27. Greenbaum LA, Hidalgo G, Chand D, Chiang M, Dell K, Kump T, et al. Obstacles to the prescribing of growth hormone in children with chronic kidney disease. *Pediatr Nephrol* 2008;23:1531–1535. [PubMed: 18528712]
28. U.S. Renal Data System. USRDS 2007 Annual Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
29. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2007 Annual Report. 2007.
30. Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. *Kidney Int* 2002;62:648–653. [PubMed: 12110030]
31. Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. *Pediatr Nephrol* 2008;23:27–39. [PubMed: 17120060]
32. Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. *Am J Cardiol* 1995;75:45B–52B. [PubMed: 7801862]
33. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143–3421. [PubMed: 12485966]
34. Mitsnefes MM, Ho PL, McEnery PT, Schurman S. Hypertension and progression of chronic renal failure in children: The North American Pediatric Renal Transplant Cooperative Study report. *J Am Soc Nephrol* 2002;13:426A.
35. Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. [see comment]. *Hypertension* 2008;52:631–637. [PubMed: 18725579]

36. Sorof JM, Cardwell G, Franco K, Portman RJ. Ambulatory blood pressure and left ventricular mass index in hypertensive children. *Hypertension* 2002;39:903–908. [PubMed: 11967247]
37. Lande MB, Carson NL, Roy J, Meagher CC. Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. *Hypertension* 2006;48:40–44. [PubMed: 16735644]
38. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. *Circulation* 1999;99:2434–2439. [PubMed: 10318666]
39. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimalmedial thickness and left ventricular hypertrophy in children with elevated blood pressure. *Pediatrics* 2003;111:61–66. [PubMed: 12509555]
40. Mitsniefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. *J Pediatr* 2006;149:671–675. [PubMed: 17095341]
41. Mitsniefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR, et al. Impaired left ventricular diastolic function in children with chronic renal failure. *Kidney Int* 2004;65:1461–1466. [PubMed: 15086489]
42. Mitsniefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR, et al. Abnormal cardiac function in children after renal transplantation. *Am J Kidney Dis* 2004;43:721–726. [PubMed: 15042550]
43. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. *Am J Kidney Dis* 1998;32:S142–S156. [PubMed: 9820472]
44. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Management of Dyslipidemias in Patients with Kidney Disease. *Am J Kidney Dis* 2003;41:S1–S91. [PubMed: 12751048]
45. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. *Kidney Int* 2001;59:260–269. [PubMed: 11135079]
46. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. *Am J Kidney Dis* 2005;46:799–811. [PubMed: 16253719]
47. Matteucci MC, Wuhl E, Picca S, Mastrostefano A, Rinelli G, Romano C, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. *J Am Soc Nephrol* 2006;17:218–226. [PubMed: 16280471]
48. El-Husseini AA, Sheashaa HA, Hassan NA, El-Demerdash FM, Sobh MA, Ghoneim MA. Echocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation. *Pediatr Transplant* 2004;8:249–254. [PubMed: 15176962]
49. Morris KP, et al. Non-cardiac benefits of human recombinant erythropoietin in end-stage renal failure and anaemia. *Arch Dis Child* 1993;69:580–586. [PubMed: 8257180]
50. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? *Clinical Journal of The American Society of Nephrology: CJASN* 2008;3:505–521. [PubMed: 18184879]
51. Mitsniefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, et al. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. *J Am Soc Nephrol* 2005;16:2796–2803. [PubMed: 16049067]
52. Goldstein SL, Leung JC, Silverstein DM. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. *Clinical Journal of The American Society of Nephrology: CJASN* 2006;1:979–986. [PubMed: 17699316]
53. Sylvestre LC, Fonseca KP, Stinghen AE, Pereira AM, Meneses RP, Pecoits-Filho R. The malnutrition and inflammation axis in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2007;22:864–873. [PubMed: 17340148]
54. Balakrishnan VS, Guo D, Rao M, Jaber BL, Tighiouart H, Freeman RL, et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. *Kidney Int* 2004;65:1449–1460. [PubMed: 15086488]

55. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney Int* 2007;72:549–556. [PubMed: 17579660]
56. Badiou S, Cristol JP, Jaussent I, Terrier N, Morena M, Maurice F, et al. Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. *Clinical Journal of The American Society of Nephrology: CJASN* 2008;3:423–430. [PubMed: 18235144]
57. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. *Circulation* 2002;106:100–105. [PubMed: 12093777]
58. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med* 2000;342:1478–1483. [PubMed: 10816185]
59. Barker DJ. The developmental origins of insulin resistance. *Horm Res* 2005;64:2–7. [PubMed: 16439838]
60. Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. *Kidney Int* 2005;97:S68–S77.
61. Bayrakci US, Schaefer F, Duzova A, Yigit S, Bakkaloglu A. Abnormal circadian blood pressure regulation in children born preterm. *J Pediatr* 2007;151:399–403. [PubMed: 17889077]
62. Hemachandra AH, Klebanoff MA, Furth SL. Racial disparities in the association between birth weight in the term infant and blood pressure at age 7 years: results from the Collaborative Perinatal Project. *J Am Soc Nephrol* 2006;17:2576–2581. [PubMed: 16870709]
63. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr* 2004;79:820–825. [PubMed: 15113720]
64. Shroff R, Egerton M, Bridel M, Shah V, Hiorns M, Donald A, et al. Vitamin D, inflammation and vascular calcification in children on dialysis. *Pediatr Nephrol* 2007;22:1448.
65. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002;110:229–238. [PubMed: 12122115]
66. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? *Kidney Int* 2005;68:1973–1981. [PubMed: 16221197]
67. Chesney RW, Brewer E, Moxey-Mims M, Watkins S, Furth SL, Harmon WE, et al. Report of an NIH task force on research priorities in chronic kidney disease in children. *Pediatr Nephrol* 2006;21:14–25. [PubMed: 16252095]
68. Rotundo A, Nevins TE, Lipton M, Lockman LA, Mauer SM, Michael AF. Progressive encephalopathy in children with chronic renal insufficiency in infancy. *Kidney Int* 1982;21:486–491. [PubMed: 7087284]
69. McGraw ME, Haka-Ikse K. Neurologic-developmental sequelae of chronic renal failure in infancy. *J Pediatr* 1985;106:579–583. [PubMed: 3884761]
70. Polinsky MS, Kaiser BA, Stover JB, Frankenfield M, Baluarte HJ. Neurologic development of children with severe chronic renal failure from infancy. *Pediatr Nephrol* 1987;1:157–165. [PubMed: 3153274]
71. Bock GH, Connors CK, Ruley J, Samango-Sprouse CA, Conry JA, Weiss I, et al. Disturbances of brain maturation and neurodevelopment during chronic renal failure in infancy. *J Pediatr* 1989;114:231–238. [PubMed: 2464681]
72. Qvist E, Pihko H, Fagerudd P, et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. *Pediatr Transplantation* 2002;6:53–62.
73. Valanne L, Qvist E, Jalanko H, Holmberg C, Pihko H. Neuroradiologic findings in children with renal transplantation under 5 years of age. *Pediatr Transplantation* 2004;8:44–51.
74. Warady BA. Neurodevelopment of infants with end-stage renal disease: is it improving? *Pediatr Transplantation* 2002;6:5–7.
75. Hulstijn-Dirkmaat GM, Damhuis IH, Jetten ML, Koster AM, Schroder CH. The cognitive development of pre-school children treated for chronic renal failure. *Pediatr Nephrol* 1995;9:464–469. [PubMed: 7577410]

76. Honda M, Kamiyama Y, Kawamura K, Kawahara K, Shishido S, Nakai H, et al. Growth, development and nutritional status in Japanese children under 2 years on continuous ambulatory peritoneal dialysis. *Pediatr Nephrol* 1995;9:543–548. [PubMed: 8580004]
77. Warady BA, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating peritoneal dialysis in early infancy. *Pediatr Nephrol* 1999;13:759–765. [PubMed: 10603115]
78. Ledermann SE, Scanes ME, Fernando ON, Duffy PG, Madden SJ, Trompeter RS. Long-term outcome of peritoneal dialysis in infants. *The Journal of Pediatrics* 2000;136:24–29. [PubMed: 10636969]
79. Madden SJ, Ledermann SE, Guerrero-Blanco M, Bruce M, Trompeter RS. Cognitive and psychosocial outcome of infants dialysed in infancy. *Child Care Health Dev* 2003;29:55–61. [PubMed: 12534567]
80. Mendley SR, Zelko FA. Improvement in specific aspects of neurocognitive performance in children after renal transplantation. *Kidney Int* 1999;56:318–323. [PubMed: 10411708]
81. Brouhard BH, Donaldson LA, Lawry KW, McGowan KR, Drotar D, Davis I, et al. Cognitive functioning in children on dialysis and post-transplantation. *Pediatr Transplantation* 2000;4:261–267.
82. Lawry KW, Brouhard BH, Cunningham RJ. Cognitive functioning and school performance in children with renal failure. *Pediatr Nephrol* 1994;8:326–329. [PubMed: 7917859]
83. Gerson AC, Butler R, Moxey-Mims M, et al. Neurocognitive outcomes in children with chronic kidney disease: current findings and contemporary endeavors. *Ment Retard Dev Disabil Res* 2006;12:208–215.
84. Slickers J, Duquette P, Hooper S, Gipson D. Clinical predictors of neurocognitive deficits in children with chronic kidney disease. *Pediatr Nephrol* 2007;22:565–572. [PubMed: 17180361]
85. Fennell RS, Fennell EB, Carter RL, Mings EL, Klausner AB, Hurst JR. Association between renal function and cognition in childhood chronic renal failure. *Pediatr Nephrol* 1990;4:16–20. [PubMed: 2206874]
86. Fennell RS, Fennell EB, Carter RL, Mings EL, Klausner AB, Hurst JR. A longitudinal study of the cognitive function of children with renal failure. *Pediatr Nephrol* 1990;4:11–15. [PubMed: 2206873]
87. Gipson DS, Hooper SR, Duquette PJ, Wetherington CE, Stellwagen KK, Jenkins TL, et al. Memory and executive functions in pediatric chronic kidney disease. *Child Neuropsychol* 2006;12:391–405. [PubMed: 16952886]
88. Lande MB, Kaczorowski JM, Auinger P, et al. Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United States. *J Pediatr* 2003;143:720–724. [PubMed: 14657815]
89. Duquette PJ, Hooper SR, Wetherington CE, Icard PF, Gipson DS. Brief report: intellectual and academic functioning in pediatric chronic kidney disease. *J Pediatr Psychol* 2007;32:1011–1017. [PubMed: 17556399]
90. Icard PF, Hower SJ, Kuchenreuther AR, Hooper SR, Gipson DS. The transition from childhood to adulthood with ESRD: educational and social challenges. *Clin Nephrol* 2007;68:1–7. [PubMed: 17703829]
91. Groothoff JW, Grootenhijs M, Dommerholt A, Gruppen MP, Offringa M, Heymans HS. Impaired cognition and schooling in adults with end stage renal disease since childhood. *Arch Dis Child* 2002;87:380–385. [PubMed: 12390905]
92. Furth S, Cole S, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, et al. Design and Methods of the Chronic Kidney Disease in Children (CKiD) Prospective Cohort Study. *Clin J Am Soc Nephrol* 2006;1:1006–1015. [PubMed: 17699320]

Table 1
Causes of Poor Growth in Children with CKD

Intrauterine growth retardation
Metabolic acidosis
Malnutrition
Renal osteodystrophy
Glucocorticoid use
Salt wasting
Perturbations in the GH-IGF-I axis

Abbreviations: CKD, chronic kidney disease; GH-IGF-I, growth hormone-insulinlike growth factor I.